🇺🇸 FDA
Patent

US 10072084

Dual specific immunotoxin for brain tumor therapy

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10072084 (Dual specific immunotoxin for brain tumor therapy) held by The United States of America as Represented by the Secretary Department of Health and Human Services (NIH) expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary Department of Health and Human Services (NIH)
Grant date
Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K38/00, A61K39/39558